Lonza, chemical and biological manufacturer, has signed a long-term commercial supply agreement with a biopharmaceutical company, Portola Pharmaceuticals, to secure the supply of AndexXa (andexanet alfa).
Partnership cogs
The companies are strengthening relations with this agreement following their successful collaboration on the clinical manufacturing of the universal recombinant protein reversal agent for patients on FXa inhibitors who experience a major bleed or need urgent surgery (AndexXa).
As per the agreement, Lonza will extend current manufacturing commitments at its Porrino facility and add long-term manufacturing production in Visp for AndexXa. This expanded manufacturing collaboration guarantees access to Lonza’s capacity for Portola and allows coverage of the full range of anticipated demand scenarios for commercial supply. Additionally, through this agreement Lonza adds the first customer to its new manufacturing complex Ibex.
“This significant agreement with Portola deepens our existing collaboration globally,” explained Marc Funk, COO for Lonza’s Pharma&Biotech segment. “The scale up and transfer of the manufacture of AndexXa to Lonza’s new Ibex facility in Visp will ensure quantities of product needed for patients can be met for the long-term from a secure second Lonza supply site.”